Humacyte (HUMA) Gross Margin (2025 - 2026)
Humacyte (HUMA) reported Gross Margin of 311.72% for Q1 2026, down 38328.0% year-over-year from N/an in Q1 2025, and up 83.1% quarter-over-quarter from 1844.75% in Q4 2025.
Humacyte (HUMA) Gross Margin (2025 - 2026) Analysis & Trends
Humacyte (HUMA) has 2 years of Gross Margin data on file, last reported at 311.72% in Q1 2026.
- Gross Margin for Q1 2026 came in at 311.72%, down 38328.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 475.05% (down 54662.0% YoY), and the FY2025 annual result was 376.05%, changed N/A from the prior year.
- Gross Margin grew to 311.72% in Q1 2026 per HUMA's latest filing, from 1844.75% in the prior quarter.
- Over five years, Gross Margin peaked at 71.57% in Q1 2025 and troughed at 1844.75% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 79.04% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Humacyte | 183.21 Mn | 134.67 Mn | -1.54 Mn | -311.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -311.72% |
| Dec 31, 2025 | -1,844.75% |
| Sep 30, 2025 | 65.47% |
| Jun 30, 2025 | 29.24% |
| Mar 31, 2025 | 71.57% |